{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T15:16:11Z","timestamp":1766934971823,"version":"3.40.5"},"reference-count":18,"publisher":"Media Sphere Publishing House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:p>Objective. To conduct a comparative analysis between the original alteplase and its biosimilar in terms of efficacy and safety in real clinical practice in the Republic of Belarus. Material and methods. The cohort study included 420 patients. All included patients underwent thrombolytic therapy with alteplase within 4.5 hours of the onset of stroke symptoms according to the approved tactics of the Republic of Belarus and international recommendations. The patients were divided into 2 groups: 215 received the drug Revelisa, 205 \u2014 Actilyse. Results. The patients were comparable in gender, age, ASPECTS assessment, but had statistically significant difference in NIHSS was found, due to the large number of patients with NIHSS=16\u201425 in the Actilyse group. The assessment of premorbid disability also showed a statistically significant difference: there were more patients in the Revelisa group who had functional limitations of varying degrees before the disease, 83 (38.6%) versus 62 (28.3%) patients in the comparison group. Clinical outcomes were comparable, the proportion of patients achieving mRS=0-1 at discharge was 41.5% in group A and 42.8% in group P. The Revelisa demonstrated a statistically significant lower number of deaths in 15 (7.0%) and 29 (14.1%) in the comparison group. The development of a greater number of clinically insignificant petechial hemorrhages was noted after the use of Actilyse. Conclusion. The analysis demonstrated a high level of safety in the use of alteplase preparations in routine practice. The compared fibrinolytics had comparable effectiveness in achieving functional independence after ischemic stroke, despite the more premorbid disability of patients who received a biosimilar.<\/jats:p>","DOI":"10.17116\/jnevro202412403249","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T14:26:34Z","timestamp":1711031194000},"page":"49","source":"Crossref","is-referenced-by-count":2,"special_numbering":"Vyp. 2","title":["Comparative characteristics of the efficacy and safety of the original alteplase and its complete biosimilar in the treatment of ischemic stroke in real clinical practice"],"prefix":"10.17116","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3905-0433","authenticated-orcid":false,"given":"S.V.","family":"Marchenko","sequence":"first","affiliation":[{"name":"Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology","place":["Minsk, Belarus"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3695-1771","authenticated-orcid":false,"given":"U.V.","family":"Hil","sequence":"additional","affiliation":[{"name":"Grodno State Medical University","place":["Grodno, Belarus"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6023-5801","authenticated-orcid":false,"given":"I.G.","family":"Hil","sequence":"additional","affiliation":[{"name":"City Clinical Hospital of Emergency Medical Care","place":["Minsk, Belarus"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202412403249-1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00252-0"},{"key":"key-10.17116\/jnevro202412403249-2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.12.6.723"},{"key":"key-10.17116\/jnevro202412403249-3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.025825"},{"key":"key-10.17116\/jnevro202412403249-4","unstructured":"Resolution of the Ministry of Health of the Republic of Belarus 01\/18\/2018 No. 8 \u00abOn approval of the clinical protocol \u00abDiagnosis and treatment of patients with diseases of the nervous system (adult population)\u00bb. (In Russ.)"},{"key":"key-10.17116\/jnevro202412403249-5","unstructured":"Clinical recommendations. Ischemic stroke and transient ischemic attack in adults. ID:171. 2021. (In Russ.). Link active at 02\/12\/2024. https:\/\/cr.minzdrav.gov.ru\/recomend\/171_2"},{"key":"key-10.17116\/jnevro202412403249-6","doi-asserted-by":"publisher","DOI":"10.1177\/2396987321989865"},{"key":"key-10.17116\/jnevro202412403249-7","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211"},{"key":"key-10.17116\/jnevro202412403249-8","doi-asserted-by":"publisher","DOI":"10.29296\/25419218-2019-04-06"},{"key":"key-10.17116\/jnevro202412403249-9","doi-asserted-by":"publisher","DOI":"10.30895\/2221-996X-2019-19-1-39-49"},{"key":"key-10.17116\/jnevro202412403249-10","doi-asserted-by":"publisher","DOI":"10.18565\/therapy.2019.2.42-57"},{"key":"key-10.17116\/jnevro202412403249-11","unstructured":""},{"key":"key-10.17116\/jnevro202412403249-12","unstructured":"Rules for conducting research on biological medicinal products of the Eurasian Economic Union. Approved on November 16, 2016 No. 89. Link active as of 02.12.2024. (In Russ.).  https:\/\/docs.eaeunion.org\/docs\/ru-ru\/01411954\/cncd_21112016_89"},{"key":"key-10.17116\/jnevro202412403249-13","unstructured":"Instructions for medical use of the drug Reveliza LP-005158 dated April 24, 2023. Link active as of 02\/12\/2024. (In Russ.). https:\/\/grls.rosminzdrav.ru Instruction for medical use Revelisa LP-005158"},{"key":"key-10.17116\/jnevro202412403249-14","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202212212242"},{"key":"key-10.17116\/jnevro202412403249-15","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202312308255"},{"key":"key-10.17116\/jnevro202412403249-16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804656"},{"key":"key-10.17116\/jnevro202412403249-17","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1590-8"},{"key":"key-10.17116\/jnevro202412403249-18","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.660415"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:43:17Z","timestamp":1745386997000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2024\/3-2\/1199772982024032049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,21]]}},"alternative-id":["10.17116\/jnevro202412403249"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202412403249","relation":{},"ISSN":["1997-7298"],"issn-type":[{"type":"print","value":"1997-7298"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}